Promega, JA6015, SIRPα/CD47 Blockade Bioassay

Measure Potency and Stability of Biologics that Bind and Block SIRPα/CD47 Interactions
Prequalified according to ICH guidelines
96- and 384-well plate formats
No primary cell culture required
Supplied in convenient thaw-and-use format; also available in cell propagation model (CPM) format
Specifications：
SIRPα Effector Cells GA131A 1 × 0.5ml
CD47/FcγR-A CHO-K1 Target Cells GA125A 1 × 0.5ml
Fetal Bovine Serum J121A 1 × 4ml
Ham's F-12 Medium J123A 1 × 25ml
RPMI 1640 Medium G708A 1 × 36ml
Bio-Glo-NL™ Luciferase Assay Buffer J308A 1 × 10ml
Bio-Glo-NL™ Luciferase Assay Substrate J309A 1 × 200μl
SIRPα Effector Cells GA131A 5 × 0.5ml
CD47/FcγR-A CHO-K1 Target Cells GA125A 5 × 0.5ml
Fetal Bovine Serum J121A 5 × 4ml
Ham's F-12 Medium J123A 5 × 25ml
RPMI 1640 Medium G708A 5 × 36ml
Bio-Glo-NL™ Luciferase Assay Buffer J308A 5 × 10ml
Bio-Glo-NL™ Luciferase Assay Substrate J309A 5 × 200μl
CD47/FcγR-A CHO-K1 Target Cells (CPM) GA120A 2 × 1ml
SIRPα Effector Cells (CPM) GA129A 2 × 1ml
SIRPα Effector Cells (CPM) GA129A 50 × 1ml
CD47/FcγR-A CHO-K1 Target Cells (CPM) GA120A 50 × 1ml
Control Ab, Anti-SIRPα K125A 1 × 50μg
Antibody-dependent cellular phagocytosis (ADCP) is an important mechanism-of-action (MOA) for antibody-based immunotherapies. ADCP is regulated by a complex network of checkpoints, including SIRPα and CD47, that facilitate removal of aberrant or infected cells while preserving healthy tissues. Despite its important physiological role, the SIRPα/CD47 checkpoint contributes to immune escape by tumor cells, many of which overexpress CD47 and thereby evade phagocytosis. Biologics that inhibit SIRPα/CD47 interaction enhance phagocytosis of tumor cells in vitro and have shown promising therapeutic efficacy.
Current methods for assessing the activity of SIRPα/CD47 checkpoint inhibitors rely on primary monocyte-derived macrophages and direct measurement of phagocytosis. These assays are laborious and highly variable due to their reliance on donor cells, complex assay protocols and unqualified assay reagents. As a result, these assays are difficult to establish in a quality-controlled setting.
The SIRPα/CD47 Blockade Bioassay is a bioluminescent reporter cell-based assay used to measure the potency and stability of Fc-silent or Fc-null ligands and antibodies that bind and block SIRPα and CD47 interactions. For Fc-functional inhibitors, we recommend using the SIRPα/CD47 Blockade Bioassay, Fc-Dependent.